Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer. Unlike ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

"Proteogenomics provides a powerful approach to refine biomarker discovery and reveal critical mechanisms underlying drug resistance or novel vulnerabilities in HER2+ breast cancer," said co ...

ACCURATE determination of HER-2 status in breast cancer is essential for guiding targeted therapy and improving clinical ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU. The ...